edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Aditxt
Edison Investment Research is terminating coverage on Aditxt. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Aditxt — 2 videos in collection
Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. The company’s immune mapping technologies are designed to provide a personalised immune profile. Its immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.
In this webinar, Aditxt’s CEO, Amro Albanna, is joined by Jason Kolbert, a research analyst at Dawson James. Jason asks Amro about overall business updates and milestones and the company’s acquisition strategy.
Get access to the very latest content matched to your personal investment style.